Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (271-280 of 323) with videos related to

Pageof 33
Sort By:
Blood Advances|November 8, 2019
Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cellsTomasz Sewastianik, Maria Luisa Guerrera, Keith Adler, et al.
American Journal of Hematology|March 15, 2026
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström MacroglobulinemiaJorge J Castillo, Andrew R Branagan, Alberto Guijosa, et al.
Seminars in Hematology|May 22, 2025
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathyShirley D'Sa, Jahanzaib Khwaja, Signy Chow, et al.
Blood|January 17, 2013
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionLian Xu, Zachary R Hunter, Guang Yang, et al.
Oncoimmunology|August 17, 2017
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphomaJulie S Nielsen, Andrew R Chang, Darin A Wick, et al.
Blood|March 3, 2018
BTK<sup>Cys481Ser</sup> drives ibrutinib resistance via ERK1/2 and protects BTK<sup>wild-type</sup> MYD88-mutated cells by a paracrine mechanismJiaji G Chen, Xia Liu, Manit Munshi, et al.
Blood|March 13, 2008
Targeting NF-kappaB in Waldenstrom macroglobulinemiaXavier Leleu, Jérôme Eeckhoute, Xiaoying Jia, et al.
Seminars in Hematology|May 16, 2025
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitorsJorge J Castillo, Francesco Autore, Neil L Berinstein, et al.
British Journal of Haematology|November 18, 2020
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinibJorge J Castillo, Jithma P Abeykoon, Joshua N Gustine, et al.
Leukemia|September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Pageof 33

Showing results (271-280 of 323) with videos related to

Sort By:
Pageof 33
Blood Advances|November 8, 2019
Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cellsTomasz Sewastianik, Maria Luisa Guerrera, Keith Adler, et al.
American Journal of Hematology|March 15, 2026
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström MacroglobulinemiaJorge J Castillo, Andrew R Branagan, Alberto Guijosa, et al.
Seminars in Hematology|May 22, 2025
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathyShirley D'Sa, Jahanzaib Khwaja, Signy Chow, et al.
Blood|January 17, 2013
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionLian Xu, Zachary R Hunter, Guang Yang, et al.
Oncoimmunology|August 17, 2017
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphomaJulie S Nielsen, Andrew R Chang, Darin A Wick, et al.
Blood|March 3, 2018
BTK<sup>Cys481Ser</sup> drives ibrutinib resistance via ERK1/2 and protects BTK<sup>wild-type</sup> MYD88-mutated cells by a paracrine mechanismJiaji G Chen, Xia Liu, Manit Munshi, et al.
Blood|March 13, 2008
Targeting NF-kappaB in Waldenstrom macroglobulinemiaXavier Leleu, Jérôme Eeckhoute, Xiaoying Jia, et al.
Seminars in Hematology|May 16, 2025
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitorsJorge J Castillo, Francesco Autore, Neil L Berinstein, et al.
British Journal of Haematology|November 18, 2020
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinibJorge J Castillo, Jithma P Abeykoon, Joshua N Gustine, et al.
Leukemia|September 17, 2021
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemiaJorge J Castillo, Kirsten Meid, Joshua N Gustine, et al.
Pageof 33